๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas

โœ Scribed by Luca Arcaini; Michele Merli; Francesco Passamonti; Raffaele Bruno; Ercole Brusamolino; Paolo Sacchi; Sara Rattotti; Ester Orlandi; Elisa Rumi; Virginia Ferretti; Silvia Rizzi; Erika Meli; Cristiana Pascutto; Marco Paulli; Mario Lazzarino


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
126 KB
Volume
85
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Treatment of localized non-hodgkin's lym
โœ Koh-ichi Sakata; Masato Hareyama; Atushi Oouchi; Mitsuo Sido; Hisayasu Nagakura; ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 178 KB ๐Ÿ‘ 1 views

This report clarifies the prognostic factors for survival in localized non-Hodgkin's lymphoma (NHL) of the head and neck and defines optimal regimens for this disease. One hundred-seven untreated patients with Stage I or II NHL of the head and neck were treated with involved field radiation therapy

A randomized comparison of the efficacy
โœ Reena Nair; Gopal Ramakrishnan; Narendran N. Nair; Tapan K. Saikia; Purvish M. P ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 86 KB ๐Ÿ‘ 2 views

## BACKGROUND. Combination chemotherapy consisting of methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisolone, and bleomycin (MACOP-B) has been frequently used for the treatment of non-Hodgkin's lymphoma. This randomized study was undertaken to assess the efficacy and toxicity of th

A pilot study on the use of the proMACE-
โœ Luca Baldini; Andrea Guffanti; Paolo Gobbi; Mariangela Colombi; Massimo Federico ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 90 KB ๐Ÿ‘ 2 views

## Background: The role of intensive conventional dose chemotherapy in advanced low grade non-hodgkin's lymphomas is a matter of debate. the gruppo italiano per lo studio dei linfomi conducted a study to evaluate the efficacy and toxicity of a third-generation polychemotherapeutic regimen, promace-